Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis.
Vasilina Sotiropoulou, Fotios Sampsonas, Eirini Vasarmidi, Katerina Antoniou, Athena Gogali, Konstantinos Kostikas, Fotios Drakopanagiotakis, Paschalis Steiropoulos, George Margaritopoulos, Konstantinos Porpodis, Zoe Daniil, Ioannis Tomos, Ilias Papanikolaou, Vasilios Tzilas, Stelios Loukides, Argyrios Tzouvelekis
Front Immunol 17 1777564
摘要
摘要
INTRODUCTION: Despite their profound clinical impact and high mortality, acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) still lack any effective or standardized treatment strategies. This manuscript describes the rationale and design of a randomized, multicenter, open-label Phase III clinical trial evaluating the efficacy of intravenous immunoglobulin (IVIG) compared with usual care in hospitalized patients with AE-IPF. METHODS: This trial will enroll 196 patients across eight different sites in Greece. Inclusion criteria are designed to identify patients with AE-IPF according to the American Thoracic Society definition, while excluding those with cardiac decompensation or pulmonary embolism. The primary endpoint is a composite of all-cause in-hospital mortality or the need for intubation. Secondary endpoints include all-cause mortality at 30 and 90 days, hospital readmission or a new AE-IPF episode within 90 days, and the change in the PaO2/FiO2 ratio from hospital admission to discharge. DISCUSSION: Based on the concept that patients with IPF frequently demonstrate impaired cellular and humoral immunity, and inflammation and/or immune dysregulation may contribute to AE-IPF pathogenesis, there is a strong rationale for evaluating the therapeutic usefulness of IVIG in this setting. Retrospective data indicate that IVIG could provide clinical benefit in AE-IPF, potentially through its anti-inflammatory and immunomodulatory effects. In this trial, IVIG will be administered as an adjunct to usual care, which includes pulse corticosteroids, broad-spectrum antibiotics, prophylactic anticoagulation, and oxygen therapy. This intervention has the potential to significantly influence current treatment strategies for AE-IPF. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT07299695.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(1,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。